secwatch.observer — SEC 8-K summary
======================================

Issuer:     Eton Pharmaceuticals, Inc. (ETON)
CIK:        0001710340
Form:       8-K
Filed at:   2026-04-27T23:59:59+00:00
Accession:  0001437749-26-013369
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Eton Pharmaceuticals initiates ET-700 pilot study for Wilson disease
--------------------------------------------------------------------

- First patient dosed in double-blinded, placebo-controlled trial comparing ET-700 to Galzin and placebo.
- Study uses 64Cu PET imaging to assess intestinal copper absorption in 36 healthy volunteers.
- Topline results expected H2 2026; positive data could lead to pivotal study in early 2027.
- CEO expects peak annual U.S. sales of ET-700 could exceed $100 million if approved.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1710340/000143774926013369/0001437749-26-013369-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1710340/000143774926013369/eton20260401_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-013369

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer